Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve
Adherence to guideline-recommended bone health measures in patients with mHSPC receiving ADT was markedly suboptimal. These findings underscore the need to implement standardized institutional protocols to ensure systematic supplementation, routine DXA monitoring, and appropriate antiresorptive therapy.
Authors
- Alicia López-Abad (ORCID: https://orcid.org/0000-0003-1190-2694)
- E. Cardenas
- Paula Ruiz-Carreño (ORCID: https://orcid.org/0000-0002-1388-2706)
- Elena López‐Jiménez (ORCID: https://orcid.org/0000-0002-5179-5195)
- Francisco J. López (ORCID: https://orcid.org/0000-0001-9010-6850)
- Juan Antonio Encarnación (ORCID: https://orcid.org/0000-0003-1463-9326)
- Pablo Guzmán (ORCID: https://orcid.org/0000-0001-5847-7248)
- Enrique Cao-Avellaneda
- Miguel Sánchez‐Pérez
- Macarena I. de la Fuente
- Pedro López-Cubillana
- Nayelli Ortega-López
- Silverio Ros (ORCID: https://orcid.org/0009-0008-8616-2401)
- Cristina Rodríguez (ORCID: https://orcid.org/0000-0002-4721-7325)
- José Luis Alonso-Romero (ORCID: https://orcid.org/0000-0001-8746-2096)
- C F Manso
- Pedro Ángel López-González
Institutions
- Instituto Murciano de Investigación Biosanitaria (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Universidad de Murcia (ES)
Publication Details
- Journal
- Cancers
- Published
- 2025-12-13
- DOI
- https://doi.org/10.3390/cancers17243977
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05